Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports-Reference-Cited by-同舟云学术

Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports

Published:2020-09-22 Issue:3 Volume:87 Page:1432-1442
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Goldman Adam¹²^ORCID,Bomze David¹²³,Dankner Rachel¹⁴,Hod Hanoch²⁵,Meirson Tomer⁶,Boursi Ben²⁷⁸,Maor Elad²⁵

Affiliation:

1. Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine Tel Aviv University Israel

2. School of Medicine, Sackler Faculty of Medicine Tel‐Aviv University Israel

3. Department of Dermatology University Hospital of Zurich Zurich Switzerland

4. Unit for Cardiovascular Epidemiology The Gertner Institute for Epidemiology and Health Policy Research Ramat Gan Israel

5. Leviev Heart Center Sheba Medical Center Ramat Gan Israel

6. Azrieli Faculty of Medicine Bar‐Ilan University Israel

7. Department of Oncology, Sheba Medical Center Tel HaShomer Israel

8. Center for Clinical Epidemiology and Biostatistics University of Pennsylvania Philadelphia PA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14546

Reference42 articles.

1. Hydroxychloroquine: From Malaria to Autoimmunity

2. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL‐1‐α) and IL‐6 in human monocytes and T cells;Sperber K;J Rheumatol,1993

3. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents;Ohkuma S;Proc Natl Acad Sci USA,1978

4. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks

5. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread;Vincent MJ;Virol J,2005

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydroxychloroquine: Pharmacokinetics and Toxicity;Journal of Clinical Pharmacy and Therapeutics;2024-01-24

2. Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options;Medicina;2023-10-23

3. Reply;Arthritis & Rheumatology;2023-10-22

4. Risk of arrhythmia among new users of hydroxychloroquine: comment on the article by Hoque et al;Arthritis & Rheumatology;2023-08-30

5. Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)—Analysis of Data from Daily Practice;Microorganisms;2023-08-03